Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
MedComm - Biomaterials and Applications is Scopus-indexed (Q1, CiteScore 6.2), DOAJ. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 2769-643XVerify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (miscellaneous) | 93 / 466 | 80th | Q1 |
| Biomaterials | 65 / 146 | 55th | Q2 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present, best quartile Q1, CiteScore 6.2.
MedComm - Biomaterials and Applications is Q1 in Medicine (miscellaneous) (rank 93 of 466) and Q2 in Biomaterials (rank 65 of 146), by CiteScore 2025.
MedComm - Biomaterials and Applications is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 6.2, quartile Q1, 80th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.777, quartile Q2, with an H-index of 16.
No article processing charge is recorded for it (source: OpenAlex). Confirm on the journal's own website, since some journals charge for extras such as colour figures.
MedComm - Biomaterials and Applications is published by John Wiley and Sons Inc. Its ISSN is 2769-643X.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
MedComm - Biomaterials and Applications has an h-index of 17 and a 2-year mean of 2.13 citations per paper (OpenAlex). Its Scopus CiteScore is 6.2, quartile Q1. On 2-year citations it ranks #156 of 451 Scopus journals in Medicine (miscellaneous).
MedComm - Biomaterials and Applications published 45 papers in 2025; its busiest recent year was 2023 with 46. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2024–2026), authors are most often from China (75.5%), India (8.3%) and United States (4.8%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.